Inhibrx Biosciences financials
$104.83+3.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.3M | $0.00 | $100.0K | $0.00 | $100.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $1.3M | $0.00 | $100.0K | $0.00 | $100.0K |
| Gross margin | — | — | — | — | 100.0% | — | 100.0% | — | 100.0% |
| Operating income | -$32.1M | -$30.9M | -$30.9M | -$33.8M | -$27.4M | -$42.9M | -$49.9M | -$46.8M | -$160.9M |
| Net income | -$36.6M | -$33.4M | -$32.8M | -$35.3M | -$28.7M | -$43.3M | -$47.9M | -$43.9M | $1.86B |
| Net margin | — | — | — | — | −2204.2% | — | −47865.0% | — | 1858011.0% |
| Diluted EPS | $-2.34 | $-2.15 | $-2.11 | $-2.28 | $-1.85 | $-2.80 | $-2.99 | $-2.84 | $125.48 |
| EBITDA | -$31.6M | -$30.4M | -$30.4M | -$33.2M | -$26.7M | -$42.2M | -$49.2M | -$46.0M | -$160.4M |
| Operating cash flow | -$29.9M | -$38.0M | -$30.1M | -$33.8M | -$30.0M | -$35.9M | -$43.7M | -$30.3M | -$57.4M |
| Free cash flow | -$29.9M | -$38.0M | -$30.1M | -$33.8M | -$30.0M | -$35.9M | -$43.7M | -$30.5M | -$58.6M |
| Diluted shares | 15.7M | 15.6M | 15.5M | 15.5M | 15.5M | 15.5M | 16.0M | 15.5M | 14.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $133.3M | $161.7M | $124.2M | $153.1M | $186.6M | $216.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $176.3M | $175.0M | $100.6M | $99.9M | $99.3M | $98.7M |
| Total assets | $154.2M | $184.0M | $146.5M | $177.5M | $212.1M | $242.6M |
| Total liabilities | $207.2M | $205.0M | $138.5M | $140.6M | $143.6M | $148.2M |
| Shareholders' equity | -$53.0M | -$21.0M | $8.0M | $36.8M | $68.6M | $94.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology